Preclinical Evaluation of Podoplanin-Targeted Alpha-Radioimmunotherapy with the Novel Antibody NZ-16 for Malignant Mesothelioma

The prognosis of advanced mesothelioma is poor. Podoplanin (PDPN) is highly expressed in most malignant mesothelioma. This study aimed to evaluate the potential alpha-radioimmunotherapy (RIT) with a newly developed anti-PDPN antibody, NZ-16, compared with a previous antibody, NZ-12. Methods: The in...

Descripción completa

Detalles Bibliográficos
Autores principales: Sudo, Hitomi, Tsuji, Atsushi B., Sugyo, Aya, Kaneko, Mika K., Kato, Yukinari, Nagatsu, Kotaro, Suzuki, Hisashi, Higashi, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533940/
https://www.ncbi.nlm.nih.gov/pubmed/34685483
http://dx.doi.org/10.3390/cells10102503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533940/
https://www.ncbi.nlm.nih.gov/pubmed/34685483
http://dx.doi.org/10.3390/cells10102503

Ejemplares similares